India Approves First LAG-3 Inhibitor Combination for Advanced Melanoma Treatment
Bristol Myers Squibb has introduced RELOPDUO to the Indian market for metastatic melanoma patients. The therapy utilizes a dual-pathway immune response to combat unresectable skin cancer.
Novel Dual Immunotherapy Gains CDSCO Clearance
In a significant shift for oncology treatment in India, the Central Drugs Standard Control Organisation (CDSCO) has authorized the launch of RELOPDUO. Developed by Bristol Myers Squibb (BMS), this fixed-dose combination targets patients aged 12 and older suffering from unresectable or metastatic melanoma. The treatment represents the first LAG-3-based dual immunotherapy available in the country.
Mechanism and Clinical Foundation
The efficacy of RELOPDUO stems from its ability to simultaneously block two distinct immune checkpoints that cancer cells often exploit to evade detection. By combining nivolumab, a PD-1 inhibitor, with relatlimab, a LAG-3 inhibitor, the drug seeks to re-energize the body's natural immune response against tumors.
Approval for this therapeutic intervention rests on data extracted from the Phase 2/3 RELATIVITY-047 trial. The study demonstrated the following results:
- Significant improvements in progression-free survival compared to patients receiving nivolumab as a standalone treatment.
- Enhanced efficacy through the inhibition of the LAG-3 and PD-1 pathways.
- Broad applicability for both adult populations and pediatric patients weighing at least 40kg.
By integrating these two agents into a single dose, BMS provides a treatment protocol specifically engineered to address the complexities of advanced skin malignancies.
Source: The Hindu — Sci-Tech
